Jaguar Land Rover secures £2 billion funding following a crippling cyberattack that halted global operations, highlighting vulnerabilities in the just-in-time automotive supply chain.
Toyota aims for market recovery in China with affordable EVs amid new export regulations. The bZ3X model gains traction, while China sets stringent EV export permits.
A looming government shutdown highlights a fierce standoff between Trump's Republicans and Democrats as ideological differences stall crucial negotiations in Washington, affecting essential services nationwide.
First Brands Group LLC's Chapter 11 bankruptcy highlights significant debt challenges in subprime markets, sparking concerns over high-risk financing practices and potential investor impacts.
Denmark bans civilian drones and boosts security with NATO support ahead of a crucial EU summit, responding to rising drone threats and Russian incursions.
Former President Trump's fluctuating foreign policy and controversial remarks are eroding U.S. credibility, challenging its role in global democracy promotion and destabilizing international alliances.
Kuwait returns to the Eurobond market, led by Goldman Sachs, attracting $27.7 billion in bids, highlighting global interest in Middle Eastern sovereign debt amid fiscal challenges.
Chinese President Xi Jinping urges Trump to oppose Taiwan's independence, escalating U.S.-China tensions amid trade and tech negotiations, raising concerns over Taiwan's global standing.
The U.S. urges Taiwan to boost semiconductor production on American soil amid trade negotiations, aiming to meet half of domestic demand and mitigate reliance on Taiwan.
Eurozone inflation rises in September 2025, influenced by mixed national trends, challenging the ECB's cautious monetary policy stance amid varying country-specific conditions.
US tariffs strain China's profit margins and disrupt Japan's economy. Chinese exports decline, affecting US consumer prices, while Japan's output and sales suffer amid global trade tensions.
Genmab A/S acquires Dutch biotech firm Merus for $8 billion, bolstering cancer treatment advances with promising drug petosemtamab, poised to transform head and neck cancer therapies.